ATTEC (Autophagy-Tethering Compound) represents a novel therapeutic strategy for targeted protein degradation that harnesses the autophagy-lysosome pathway rather than the ubiquitin-proteasome system. ATTEC molecules function as molecular bridges, simultaneously binding to disease-causing target proteins and to LC3 (microtubule-associated protein 1A/1B-light chain 3), a key autophagosome protein. This tethering facilitates the selective engulfment and degradation of pathogenic proteins through macroautophagy.[1][2]
The ATTEC approach has emerged as a promising strategy for neurodegenerative diseases because it can target aggregated proteins that are difficult or impossible for the proteasome to degrade. Unlike PROTACs which require ubiquitination and proteasomal degradation, ATTECs can degrade proteins through the autophagy pathway, which handles larger aggregates and organelles.[3]
ATTEC molecules are bifunctional compounds designed with two distinct binding domains:
The key mechanistic difference from PROTACs lies in the degradation pathway:
This difference has important implications for the types of proteins that can be targeted. The autophagy-lysosome system can handle larger protein aggregates, misfolded proteins, and even entire organelles—substrates that overwhelm or evade the proteasome.[4]
| Feature | ATTEC | PROTAC | AUTOTAC |
|---|---|---|---|
| Degradation pathway | Autophagy | Proteasome | Autophagy |
| E3 ligase required | No | Yes | No |
| Can degrade aggregates | Yes | Limited | Yes |
| Molecular weight | ~400-600 Da | ~600-1000+ Da | ~500-800 Da |
| Development stage | Preclinical | Preclinical/Phase 1 | Preclinical |
| CNS delivery potential | Moderate | Challenging | Moderate |
PROTACs (Proteolysis-Targeting Chimeras) have been the dominant paradigm in targeted protein degradation. However, they face significant limitations for neurodegenerative applications:[5]
ATTECs offer potential advantages by bypassing these limitations through autophagy-mediated clearance.
AUTOTAC (Autophagy-Targeting Chimera) is a related approach that also targets autophagy but uses a different mechanism:[6]
This makes ATTEC potentially broader in applicability for proteins that are not efficiently ubiquitinated.
Huntington's disease is caused by mutant huntingtin protein (mHTT) with expanded polyglutamine repeats. The gain-of-toxic-function makes mHTT an ideal target for degradation strategies.
Research progress:
Advantages for HD:
Tau protein aggregation is a hallmark of Alzheimer's disease. ATTEC approaches for tau degradation have shown promise:
Alpha-synuclein aggregation drives Parkinson's disease and related synucleinopathies. ATTEC development for α-synuclein is at an earlier stage but shows promise:
The autophagy pathway can handle protein aggregates that overwhelm the proteasome:
ATTEC can potentially target:
Compared to PROTACs, ATTEC molecules can be designed with lower molecular weights, potentially improving CNS penetration.
Ding, Y., & Liu, J. (2023). Autophagy-tethering compounds for neurodegenerative disease treatment. Trends in Pharmacological Sciences. 2023. ↩︎
'Yamamoto, A., & Simonsen, A. (2021). The degradation pathway: A comparison between autophagy and the proteasome'. Current Opinion in Cell Biology. 2021. ↩︎
'Békés, M., Langley, D. R., & Crews, C. M. (2022). PROTAC targeted protein degraders: The past is prologue'. Nature Reviews Drug Discovery. 2022. ↩︎
Ji, C. H., et al. '(2022). AUTOTAC: A novel autophagy-inducing small molecule that targets protein aggregates'. Nature Communications. 2022. ↩︎
Liu, T., et al. (2024). Journal of Medicinal Chemistry. 2024. ↩︎